Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 06, 2015 4:54 PM ET

Healthcare Providers and Services

Company Overview of City Of Hope

Company Overview

City of Hope, a nonprofit public benefit corporation, operates City of Hope National Medical Center (the Center), City of Hope Medical Foundation, and Beckman Research Institute of the City of Hope. The Center operates a 186-bed tertiary referral center primarily for the treatment of cancer, diabetes, and other life-threatening diseases in Duarte, California. The company was founded in 1913 and is based in Duarte, California.

1500 East Duarte Road

Duarte, CA 91010

United States

Founded in 1913



Key Executives for City Of Hope

Chief Executive Officer and President
Chief Financial Officer
Age: 52
Chief Operating Officer and Executive Vice President
Chief Scientific Officer and Provost
Senior Vice President of Research Operations
Compensation as of Fiscal Year 2015.

City Of Hope Key Developments

Victoria L. Seewaldt Joins City of Hope as the Ruth Ziegler Chair in Population Sciences

Nationally breast cancer and ovarian cancer specialist Victoria L. Seewaldt, M.D., has joined City of Hope as the Ruth Ziegler Chair in Population Sciences. An expert in cancer prediction and prevention, Seewaldt will advance the institution’s efforts to ensure its research reflects and represents the diversity within City of Hope’s community. A specialist in developing risk models for aggressive cancers, particularly in women of color, Seewaldt will also serve as the associate director of the comprehensive cancer center. Seewaldt comes to City of Hope from Duke University, where she was a professor of medicine and leader of the Comprehensive Cancer Breast and Ovarian Cancer Program. She also founded the institution’s community outreach program for underserved women. Seewaldt will lead the Breast Cancer Early Detection and Health Disparities Program at City of Hope, operating a clinic for women at high risk of breast and ovarian cancers and working to better understand which cancers can be predicted, and thus prevented. She will also work with City of Hope’s community sites to gather information on the areas’ diverse population in order to gain a more thorough understanding of risk and disease progression. Seewaldt will emphasize clinical trials that focus on keeping high-risk women healthy, as opposed to those that emphasize intervention through medications, which can have serious side effects. She also will work to provide women in the community with health education and improved access to breast cancer screenings and treatment, as well as provide mentorship of young minority scholars.

Center for Gene Therapy Names John Zaia as Director at City of Hope

John A. Zaia, M.D., has been named director of the Center for Gene Therapy within City of Hope’s new Hematologic Malignancies and Stem Cell Transplantation Institute. Internationally known and respected for his groundbreaking research into potential gene therapy treatments for HIV, Zaia will maximize the potential of gene therapy not just for HIV, but also for cancer and other diseases as City of Hope expands its commitment to this revolutionary field of research.

City of Hope and Fortress Biotech Reach an Agreement to Form New Subsidiary Company, Diavax Biosciences

City of Hope and Fortress Biotech have reached an agreement to form a new subsidiary company, DiaVax Biosciences, that will develop two novel vaccines against cytomegalovirus infection, a life-threatening illness in people with weakened or underdeveloped immune systems, such as cancer patients and developing fetuses. Enlisting the defensive power of the immune system, the vaccines could open the door to a new way of treating a devastating opportunistic infection affecting hundreds of thousands worldwide. The vaccines Triplex and PepVax will be the subject of multi-site Phase II clinical trials, one of which already has begun enrollment (PepVax). The other (Triplex) will begin enrollment in fall of 2015. Supported by the National Cancer Institute, those trials could ultimately lead to even greater impact for City of Hope’s research. DiaVax has entered into an option with City of Hope for exclusive worldwide rights to a universal immunotherapeutic vaccine, called Pentamer, that could prevent the transmission of CMV in utero. Such transmission leads to thousands of cases of irreversible brain damage every year.

Similar Private Companies By Industry

Company Name Region
Ventas REIT US Holdings, LLC United States
Preferred Health Systems Insurance Company United States
Professional Home Health Service United States
Dorland Health Inc. United States
Montgomery Cancer Center, LLC United States

Recent Private Companies Transactions

Private Placement
November 26, 2014
Luminat, LLC

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact City Of Hope, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at